靶向SARS-CoV-2 S蛋白RBD的AAV疫苗可在小鼠和犬中诱导有效中和抗体滴度
研究设计并优化了多种基于AAV的疫苗(AAV-RBD(max)、AAV-RBD(wt)、AAV-2xRBD、AAV-3xRBD),靶向SARS-CoV-2 S蛋白RBD结构域。小鼠免疫后应答持久,至少六个月内维持接近峰值水平;AAV-3xRBD免疫血清含针对SARS-CoV-2假病毒的有效中和抗体,犬接种AAV-3xRBD后也可诱导强效特异性抗体。
要点
- AAV-3xRBD疫苗在小鼠中诱导的免疫应答至少维持六个月接近峰值水平。
- AAV-3xRBD免疫小鼠血清含针对SARS-CoV-2假病毒的有效中和抗体。
- 犬接种AAV-3xRBD疫苗后也可诱导强效特异性抗体。
核心结论
- 基于AAV的疫苗(包括AAV-3xRBD)可在小鼠和犬中诱导针对SARS-CoV-2 S蛋白RBD的强免疫应答,小鼠应答至少维持六个月接近峰值水平。
研究设计与样本
- 设计、优化并开发了AAV-RBD(max)、AAV-RBD(wt)、AAV-2xRBD和AAV-3xRBD四种基于AAV的疫苗,并在小鼠和犬中评估免疫原性。
主要发现
- 小鼠免疫后应答持久,至少六个月内维持接近峰值水平。
- AAV-3xRBD免疫小鼠血清含针对SARS-CoV-2假病毒的有效中和抗体。
- 犬接种AAV-3xRBD疫苗后可诱导强效特异性抗体。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has resulted in catastrophic damage worldwide. Accordingly, the development of powerful, safe, easily accessible vaccines with long-term effectiveness is understood as an urgently needed countermeasure against this ongoing pandemic. Guided by this strong promise of using AAVs, we here designed, optimized, and developed an AAV-based vaccines (including AAV-RBD(max), AAV-RBD(wt), AAV-2xRBD, and AAV-3xRBD) that elicit strong immune responses against the RBD domain of the SARS-CoV-2 S protein. These immunogenic responses have proven long-lived, with near peak levels for at least six months in mice. Notably, the sera immunized with AAV-3xRBD vaccine contains powerful neutralizing antibodies against the SARS-CoV-2 pseudovirus. Further evidence proven that potent specific antibodies could also be elicited in canines after vaccination with AAV-3xRBD vaccine.
引用
- Liu F, Feng C, Xu S, et al. An AAV vaccine targeting the RBD of the SARS-CoV-2 S protein induces effective neutralizing antibody titers in mice and canines. Vaccine. 2022. PMID: 35094871. doi:10.1016/j.vaccine.2022.01.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。